Watchlist Price Alert

Roche Holding AG (RHHBY)

OTC: RHHBY · Real-Time Price · USD

39.87

0.67 (1.71%)

At close: Jun 23, 2025, 10:00 AM

1.71% (1D)

Bid	39.73
Market Cap	257.92B
Revenue (ttm)	89.47B
Net Income (ttm)	17.76B
EPS (ttm)	1.57
PE Ratio (ttm)	25.39
Forward PE	13.57
Analyst	n/a

Ask	39.79
Volume	28,078
Avg. Volume (20D)	2,038,090
Open	39.54
Previous Close	39.20
Day's Range	39.51 - 39.88
52-Week Range	33.76 - 44.31
Beta	0.17

About RHHBY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RHHBY

Website n/a

Full Company Profile

Why Price Moved

9 months ago

-5.89%

Roche shares are trading lower following weight lo... Unlock content with Pro Subscription

News

2 days ago · businesswire.com

Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio...

6 days ago · seekingalpha.com

Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue

Genentech and AbbVie noted that Venclexta failed to help treat patients with newly diagnosed higher-risk MDS; However, this drug has already been approved for several other hematological indications. ...

6 days ago · businesswire.com

Genentech Provides Update on Phase III Verona Study

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) ...

6 days ago · zacks.com

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.

1 week ago · wsj.com

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

1 week ago · businesswire.com

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, a...

2 weeks ago · reuters.com

Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death com...

2 weeks ago · youtube.com

I own gold, yen and German bunds, 'won't own U.S. treasuries at all': David Roche

David Roche from Quantum Strategy criticizes President Trump's intention to influence the Fed on monetary policy.

2 weeks ago · wsj.com

Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

3 weeks ago · businesswire.com

Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezo...

Load More News